Monoamine metabolism during chronic benzodiazepine treatment and withdrawal.
Long-term normal-dose benzodiazepine treatment in seven patients was associated with reduced urinary excretion of MOPEG (4-hydroxy-3-methoxy-phenylglycol). Following the discontinuation of the drugs a characteristic withdrawal reaction occurred, with an increase towards normal values of the MOPEG excretion levels and changes in the excretion of 5-HIAA (5-hydroxyindoleacetic acid). No significant changes in the 24-hr urinary excretion of free cortisol or HMMA (3-methoxy-hydroxy-mandelic acid) were detected.
D000328:Adult; D014151:Anti-Anxiety Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001569:Benzodiazepines; D004311:Double-Blind Method; D005260:Female; D006018:Glycols / Q000652:urine*; D006719:Homovanillic Acid / Q000652:urine*; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000652:urine*; D008134:Long-Term Care; D008297:Male; D008734:Methoxyhydroxyphenylglycol / Q000652:urine*; D010648:Phenylacetates / Q000652:urine*; D013375:Substance Withdrawal Syndrome / Q000652:urine*; D014642:Vanilmandelic Acid / Q000652:urine
D014151:Anti-Anxiety Agents; D006018:Glycols; D010648:Phenylacetates; D001569:Benzodiazepines; D008734:Methoxyhydroxyphenylglycol; D006897:Hydroxyindoleacetic Acid; D014642:Vanilmandelic Acid; D006719:Homovanillic Acid